Key result
Antihypertensive monotherapy within one month of diagnosis is linked to better BP control versus later initiation.
Why the study?
Adults with hypertension have fewer cardiovascular events if controlled within 6 months of diagnosis, but they are often excluded from control metrics during this window.
Does initiating antihypertensive monotherapy within the first month of diagnosis improve blood pressure control in adults with newly diagnosed hypertension?
Cohort (n=15,422)
Yes
Does initiating antihypertensive monotherapy within the first month of diagnosis improve blood pressure control in adults with newly diagnosed hypertension?
Answers are grounded in this paper and cite their sources.
Initiating antihypertensive monotherapy within the first month of diagnosis significantly improves blood pressure control between 6 and 30 months compared to delayed treatment.
BACKGROUND: Adults with hypertension have fewer cardiovascular events if controlled within the first 6 months of diagnosis, during which time they are excluded from many hypertension control metrics. We compared blood pressure (BP, mm Hg) control rates from 6 to 42 months in adults with hypertension who did or did not have antihypertensive treatment initiated (TI) with monotherapy during the first month after diagnosis, irrespective of subsequent changes in antihypertensive pharmacotherapy. METHODS: A retrospective cohort of 15 422 patients, mean age 56.0±14.8 years, from 5 health care organizations, was identified with previously undiagnosed and untreated hypertension. BP control (<140/<90) and TI on visits with uncontrolled readings were assessed as a function of time since diagnosis, up to 42 months. Logistic regression models provided estimates of the odds of TI for initial BP, stratified by race, sex, and diagnosed diabetes. Cox proportional hazards regression estimated the hazard ratio of BP control over time. CONCLUSIONS: TI within the first month after diagnosis in contrast to later time points, leads to better BP control at 6 to 30 months, which is associated with better clinical outcomes and performance on standard hypertension control metrics. While better control is sustained for 30 months, treatment with monotherapy during the first month following diagnosis was insufficient to control hypertension in >30% of patients.
No takes yet. Share an insight, caveat, or question.
Barrett et al. (2025) conducted a cohort in Hypertension (n=15,422). Antihypertensive treatment initiated with monotherapy during the first month after diagnosis vs. No antihypertensive treatment initiated during the first month was evaluated on Blood pressure control (<140/<90 mm Hg) over time (p=<0.001). Initiating antihypertensive monotherapy within the first month after diagnosis leads to better blood pressure control at 6 to 30 months compared to later initiation (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: